< Back to search
Filter
1

Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC

for
Advanced Cancer, Clear Cell Renal Cell Carcinoma
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT05663710

Phase1, Phase2, Recruiting

A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body

for
Melanoma, Clear-Cell Renal-Cell Carcinoma (ccRCC),
Location: North Haven CT, Lake Success NY, Chapel Hill NC,
Sponsor: Regeneron Pharmaceuticals

Sex: All

Age: 18+

Code: NCT06413680

Phase1, Phase2, Recruiting

A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit

for
Gastrointestinal Stromal Tumors, Small-cell Lung Cancer,
Location: Cleveland OH, Ann Arbor MI, Houston TX, Portland OR
Sponsor: Novelty Nobility, Inc.

Sex: All

Age: 18+

Code: NCT06805825

Phase1, Recruiting

Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma

for
Carcinoma, Renal Cell
Location: St Louis MO, Houston TX, Orange CA, Palo Alto CA,
Sponsor: Oncorena AB

Sex: All

Age: 18+

Code: NCT05287945

Phase1, Phase2, Recruiting

Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study

for
Clear Cell Renal Cell Carcinoma
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT07187869

Phase1, Recruiting

Interested in new metastatic pancreatic adenocarcinoma trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

for
Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer,
Location: Orange City FL, Clermont FL, Detroit MI, Atlanta GA,
Sponsor: Inhibrx Biosciences, Inc

Sex: All

Age: 18+

Code: NCT04198766

Phase1, Phase2, Recruiting

Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery

for
Clear Cell Renal Cell Carcinoma,
Location: Irvine CA, Duarte CA
Sponsor: City of Hope Medical Center

Sex: All

Age: 18+

Code: NCT07037004

Phase2, Recruiting

GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours

for
Alveolar Soft Part Sarcoma, Renal Cell Carcinoma,
Location: Toronto, Calgary
Sponsor: Canadian Cancer Trials Group

Sex: All

Age: 15+

Code: NCT07297667

Phase1, Recruiting

Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy

for
Breast Cancer (Triple Negative Breast Cancer (TNBC)),
Location: Nashville TN
Sponsor: Jessica Mezzanotte Sharpe

Sex: All

Age: 18+

Code: NCT07555210

Recruiting

Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors

for
Solid Tumor, Small Cell Lung Cancer (SCLC),
Location: Fort Worth TX, West Valley City UT, Los Angeles CA
Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.

Sex: All

Age: 18+

Code: NCT07517198

Phase1, Recruiting

Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma

for
Clear Cell Renal Cell Carcinoma
Location: Oklahoma City OK
Sponsor: University of Oklahoma

Sex: All

Age: 18+

Code: NCT07223541

Phase2, Recruiting

Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)

for
Cancer, Immunotherapy, Advanced Solid Tumors Cancer,
Location: Frederick MD, St Louis MO, Springfield MO,
Sponsor: Elephas

Sex: All

Age: 18+

Code: NCT07327489

Recruiting

Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)

for
Clear Cell Renal Cell Carcinoma
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT07187778

Phase2, Recruiting

Neoadjuvant Zanzalintinib Plus Nivolumab in Patients With Locally Advanced and/or Inoperable Clear Cell Renal Cell Carcinoma With or Without Non-measurable Metastasis

for
Locally Advanced Renal Cell Carcinoma
Location: Richmond VA, St Louis MO, Dallas TX
Sponsor: Qian Qin

Sex: All

Age: 18+

Code: NCT06794229

Phase2, Recruiting

Phase 1 Study Of LNK001 In Advanced Or Metastatic Clear Cell Renal Cell Carcinoma

for
Clear Cell Renal Cell Carcinoma
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18 - 70

Code: NCT07564232

Phase1, Recruiting

Ivonescimab Prior to Surgery for the Treatment of High-Risk Localized Clear Cell Renal Cell Cancer

for
Localized Clear Cell Renal Cell Carcinoma,
Location: Duarte CA
Sponsor: City of Hope Medical Center

Sex: All

Age: 18+

Code: NCT07226544

Phase2, Recruiting

Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE-RCC)

for
Active Surveillance, Clear Cell Renal Cell Carcinoma
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT07023432

Phase2, Recruiting

A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases

for
Brain Metastases, Renal Cell Carcinoma
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT05048212

Phase2, Recruiting

Study of DCC-2812 in Participants With Advanced Genitourinary Cancers

for
Renal Cell Carcinoma, Urothelial Carcinoma,
Location: Boston MA, Philadelphia PA, Cleveland OH, Ann Arbor MI,
Sponsor: Deciphera Pharmaceuticals, LLC

Sex: All

Age: 18+

Code: NCT06966024

Phase1, Recruiting

[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

for
Sinonasal Neuroendocrine Carcinoma, Nasopharyngeal Carcinoma,
Location: Bethesda MD
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18 - 70+

Code: NCT06479811

Phase1, Recruiting